Glucose metabolism among Norplant® users in northern Nigeria

被引:3
作者
Sagay, AS
Imade, GE
Aisien, AO
Ujah, IOA
Muazu, MA
机构
[1] Univ Jos, Fac Med Sci, Dept Obstet & Gynaecol, Jos, Nigeria
[2] Univ Jos, Teaching Hosp, Dept Chem Pathol, Jos, Nigeria
关键词
Norplant; glucose metabolism; Nigerian women;
D O I
10.1016/S0010-7824(00)00131-1
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Twenty-one women who were consecutive accepters of Norplant were recruited for this study in our centre in August 1997. The patients had baseline (pre-insertion) investigations including a standard oral glucose tolerance test (OGTT). At their regular 3, 6, and 12 months follow-up visits, the OGTT was repeated and results were analyzed. The mean age of the clients was 31.3 +/- 4.51 years (range 24-40 years). The mean weights were 61.60 +/- 11.35, 57.63 +/- 7.51, 62.60 +/- 11.98, and 62.17 +/- 11.56 kg at pre-insertion, 3, 6, and 12 months follow-up visits respectively. The differences were statistically insignificant. All OGTT values at pre-insertion and at the follow-up visits were within the normal range. However, in comparison to pre-insertion levels (4.00 +/- 0.10 mmol/L), the fasting blood glucose concentration at 12 months (3.39 +/- 0.12 mmol/L) showed a statistically significant decline (p <0.001). The area under the glucose curve (AUC) rose by 5.8% (p = 0.018) at 3 months but declined by 5.8% (p = 0.110) and 7.3% (p = 0.103) at 6 and 12 months, respectively. The peak pre-insertion plasma glucose level following OGTT occurred at 30 min. At 3 months, the peak OGTT glucose level occurred at 30 minutes and plateaued until 60 min while at 6 and 12 months this occurred at 60 and 90 minutes, respectively. The overall trend of OGTT results within the study period showed that 12 months of Norplant use in Northern Nigerian women has no detrimental effect on glucose metabolism. (C) 2000 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:19 / 22
页数:4
相关论文
共 12 条
[1]   Five-year evaluation of safety, efficacy and acceptability of Norplant implants in Nepal [J].
Chetri, M ;
Bhatta, A ;
Amatya, RN ;
Lama, H ;
Dunson, TR ;
Spivey, S ;
McMahan, JH ;
Balogh, S .
ADVANCES IN CONTRACEPTION, 1996, 12 (03) :187-199
[2]  
CRUBB GS, 1995, CONTRACEPTION, V52, P187
[3]  
Godsland IF, 1996, J INTERN MED, V240, P1
[4]   THE EFFECT OF CONTINUOUS SUBDERMAL LEVONORGESTREL (NORPLANT) ON CARBOHYDRATE-METABOLISM [J].
KONJE, JC ;
OTOLORIN, EO ;
LADIPO, OA .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1992, 166 (01) :15-19
[5]   INSULIN SENSITIVITY IS UNALTERED BY THE USE OF THE NORPLANT(R) SUBDERMAL IMPLANT CONTRACEPTIVE [J].
KOOPERSMITH, TB ;
LOBO, RA .
CONTRACEPTION, 1995, 51 (03) :197-200
[6]  
PASSEY RB, 1977, CLIN CHEM, V23, P131
[7]   Norplant(R) implants acceptability and user satisfaction among women in two African countries [J].
Ruminjo, JK ;
Amatya, RN ;
Dunson, TR ;
Krueger, SL ;
Chi, IC .
CONTRACEPTION, 1996, 53 (02) :101-107
[8]   THE EFFECT OF NORPLANT ON GLUCOSE-METABOLISM UNDER HYPERGLYCEMIC HYPERINSULINEMIC CONDITIONS [J].
SHAMMA, FN ;
ROSSI, G ;
HAJHASSAN, L ;
PENZIAS, AS ;
CONNOLYDIAMOND, M ;
JONES, E ;
DIAMOND, MP .
FERTILITY AND STERILITY, 1995, 63 (04) :767-772
[9]  
SINGH K, 1990, Advances in Contraception, V6, P11, DOI 10.1007/BF01849483
[10]  
*WHO, 1990, WEEKLY EPIDEMIOLOGIC, P74